Pharmacoeconomic review report : indication : for the control of serum phosphorus levels in adult patients with end-stage renal disease on dialysis. Sucroferric oxyhydroxide (Velphoro) (Vifor Fresenius Medical Care Renal Pharma Ltd.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Language:

English

Subjects (All):

Cost effectiveness.

Physical Description:

1 online resource

Edition:

Final.

Place of Publication:

Ottawa, ON : CADTH, 2019.

Summary:

Sucroferric oxyhydroxide (500 mg; Velphoro) is a non-calcium, iron-based, chewable phosphate binder indicated for the control of serum phosphorus levels in patients with end-stage renal disease (ESRD) receiving dialysis. The starting dosage is three tablets per day (1,500 mg iron) administered as one tablet (500 mg iron) three times daily with meals. The dose is titrated up or down in increments of 500 mg iron (one tablet) per day every two to four weeks until an acceptable serum phosphorus level is reached. The submitted price of sucroferric oxyhydroxide is 4.62 per tablet (daily cost: 13.87 to 18.49). The manufacturer submitted a cost-utility analysis comparing sucroferric oxyhydroxide with sevelamer hydrochloride in adult patients with ESRD receiving dialysis. The analysis was conducted over a lifetime time horizon (assumed to be 10 years) from the perspective of the Canadian health care payer.

Notes:

Description based on publisher supplied metadata and other sources.